The annual Coverage for SCD Summit provides a collaborative forum to discuss the changing landscape of healthcare coverage for sickle cell disease (SCD). This meeting brings together payers, providers, pharmaceutical manufacturers, patient groups, researchers, care teams, and policymakers to discuss ways to tackle the complexities of coverage and access to SCD treatments and care.
— — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — —
Sickle cell disease is a rare genetic disorder, affecting approximately 100,000 individuals in the U.S., and disproportionately affecting Black and Brown populations. Treatment advances are emerging, yet barriers to access contribute to underutilization. Racial inequities and health disparities add to poor health outcomes and gaps in access.
The Coverage for SCD Summit highlights best practices for payer management of sickle cell disease. Information on the complications of sickle cell disease, advances in current treatment options, and strategies to address racial health disparities through coverage policy are shared.
In 2022, the Coverage for SCD Summit offered a continuing education (CE) session for the first time that provided pharmacists, managed care specialists, and physicians the knowledge and skills they need to enhance their professional competence. The CE session, “Improving Equity and Affordability of SCD Therapies: Best Practices in Benefit Strategies and Payer Management,” was hosted from 1 – 2 PM EDT. Review the session details HERE.
Read our 2021 Convening Proceedings Report to catch up on the latest discussions and recommendations shared at last year’s Coverage for SCD Summit.
Click an image below to view the full presentation slide deck
— — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — —
Thank you to each and every sponsor for your contribution and commitment to improving access and coverage for SCD treatments and care.
Want to learn more about last year’s summit? You can find our previous agenda, speaker list and more HERE